Navigation Links
QPS Expands Clinical Trial Services with Acquisition of Qualitix
Date:3/8/2011

NEWARK, Del. and TAIPEI, Taiwan, March 8, 2011 /PRNewswire/ -- QPS, LLC, a leading full-service GLP/GCP-compliant contract research organization providing testing services to support preclinical and clinical research and development, announced the acquisition of a majority interest of Qualitix Clinical Research. Qualitix, a spin-off of the biotechnology company Genovate, Inc, is a full service CRO with offices in Taiwan and China. Genovate will retain a minority interest in Qualitix, which will be known as QPS-Qualitix Taiwan.

QPS is a global CRO supporting drug discovery and development since 1995. Its six areas of expertise include: Toxicology, DMPK, Bioanalytical, Translational Medicine, Early Stage Clinical and Late Stage Clinical Research.

Qualitix is a Contract Research Organization and Site Management Organization offering high quality, cost effective research development services to assist clients in pharmaceutical, biotechnology and medical device industries engaged in new drug development and phase I-IV multinational clinical trials.

QPS-Qualitix will have the broadest range of product development, clinical research, and regulatory services in Taiwan. With its strong Asia-Pacific regional network of CRO partners, QPS-Qualitix acts as an attractive launching point from which clients may address the rapidly growing Asian market. QPS-Qualitix also owns a subsidiary corporation called Unitix – a site management organization which affords QPS-Qualitix the unique advantage of speedy patient recruitment in the region.

State-of-the-art clinical trial management and electronic data capture systems enable QPS-Qualitix to deliver first rate data management and biostatistics services, which will complement the same streamlined clinical information capabilities offered by QPS Netherlands and QPS-Bioserve India.

"We are very happy to partner with QPS. This partnership will not only allow Qualitix to vertically integrate with QPS for more global exposure and market competitiveness, but also offer complete services from preclinical to clinical to expedite new drug development," says Dr. Jen Chen, CEO of Genovate.

"This expansion in Phase I-IV clinical capability dovetails with our recent preclinical facility acquisition here in Taiwan," says Vincent Yen, President and CEO of QPS-Taiwan. "This represents the fourth cross-border acquisition QPS has made in the last six months. Clients all over the world will now have access to an even wider range of the exceptional services they have come to expect from QPS, along with an expanding global footprint."

QPS-Qualitix has an established network of prominent Taiwanese investigators at all 22 medical centers. It is the largest local CRO with broad clinical trial expertise, handling IND trials mainly focused on oncology and metabolic disorders in Taiwan, for global filing. The depth and breadth of QPS-Qualitix's experience in this important therapeutic field attracts major clients and partners including global pharmaceutical clients as well as local pharmaceutical and biotech clients from the Asia-Pacific region.

About QPS

QPS provides GLP/GCP-compliant preclinical and clinical research services to pharmaceutical and biotechnology clients worldwide in the areas of Bioanalysis, Drug Metabolism and Pharmacokinetics, Toxicology, Translational Medicine, and Clinical Research. Founded by Dr. Ben Chien in 1995, QPS has Bioanalysis and Preclinical testing facilities at its Newark, DE headquarters; and facilities in Groningen, the Netherlands; Taipei, Taiwan; and Hyderabad, India. Early-phase clinical facilities are located in Springfield, MO; Taipei, Taiwan; Groningen, the Netherlands; and Hyderabad, India. Business development offices are maintained in the US, Europe, and Asia.

About Qualitix

Qualitix is a full service CRO based in Taipei, Taiwan and Shanghai, China, and focuses on clinical monitoring and site management services for multinational clinical trials. Its major clients and partners are international pharmaceutical and biotechnology industries. At Qualitix, well-trained Clinical Research Associates, Project Managers, Regulatory Affairs Staff, Quality Control Staff, Safety Reporters and Clinical Research Trainers produce high-quality studies with high patient enrollment rates. Major therapeutic categories covered are Infectious Disease, Cardiovascular Disease, Gastroenterology, Asthma/COPD, Immunology, Obstetrics and Gynecology, Oncology and CNS

About Genovate

Genovate Biotechnology Co., Ltd. is a fully integrated biopharmaceutical company located in Taiwan, that is committed to develop innovative medicinal products that can improve people's health and quality of life. Founded in 1995 as an alliance comprised of industry, government, and private investors, Genovate currently employs a total of approximately 120 people who develop a balanced product portfolio of proprietary drugs for a number of therapeutic indications such as lupus, oncology, urinary incontinence and Type 2 diabetes. Genovate also promotes and sells a range of pharmaceutical (niche) products from foreign pharmaceutical companies through a network of local agents in Taiwan as well as in other parts of the Asia Pacific Region.


'/>"/>
SOURCE QPS, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
2. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
3. Cellectar Expands Clinical Management Team
4. VIA Pharmaceuticals Expands Clinical Trial Program for VIA-2291 in Acute Coronary Syndrome
5. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
6. Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkins Lymphoma
7. PAREXEL Expands Global Clinical Pharmacology Capabilities
8. BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
9. Senesco Expands on Recently Announced Preclinical Pancreatic Islet Data
10. Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program
11. Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... 8, 2016   HighPoint Solutions today ... (NRG),s pharmacovigilance technology services division.  NRG is a ... an Oracle Argus Specialized partner, providing drug safety ... companies. --> --> ... sciences capabilities and provides a global scale and ...
(Date:2/8/2016)... part of a major growth and expansion initiative, Dune Medical ... Chmura as President of Dune Inc., its U.S. division. ... experience in the medical device space will play a large ... --> --> In her new ... and operational functions in the U.S. She is tasked with ...
(Date:2/8/2016)... Feb. 8, 2016 Velano Vascular, a medical ... hospitalized patients and their practitioners, announced today that the ... Velano will use the proceeds from this financing, an ... in January 2015, to support the development and commercialization ... pediatric populations. Philadelphia , ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... ... While a significant number of women and men with eating disorders report a ... that best predicts the development of an eating disorder. , At the ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... ... excited to share this important news! AHCC and the Home Health and Hospice ... Clinic, CMS' designee for official ICD coding guidance and clarifications, to address concerns ...
(Date:2/8/2016)... ... February 08, 2016 , ... The schedule is ... this country. The AutismOne 2016 Conference, which is being held May 25-29 at the ... hear elsewhere about helpful interventions and causes of chronic illness in children. , Very ...
(Date:2/7/2016)... Dallas, Texas (PRWEB) , ... February 07, 2016 ... ... its new MyDecision™ program. MyDecision™ empowers employers and organizations with the tools and ... , MyDecision™ combines three elements to cut the cost of providing employee healthcare ...
(Date:2/6/2016)... ... February 06, 2016 , ... With the FCPX LUT: Summer ... grades to their footage. A LUT is a Lookup Table that contains a mathematical ... color indicated by the table. By manipulating each pixel, LUT's can change each color ...
Breaking Medicine News(10 mins):